Products Categories
| CAS No.: | 143-67-9 |
|---|---|
| Name: | Vinblastine sulfate |
| Article Data: | 3 |
| Molecular Structure: | |
|
|
|
| Formula: | C46H58N4O9 |
| Molecular Weight: | 810.988 |
| Synonyms: | Alkaban-AQ;Exal;VLBmonosulfate;Velban;Velbe;Velsar;Vincaleukoblastine derivative;vincaleukoblastine, (2'beta)-;(2'beta)-Vincaleukoblastine;Vincaleukoblastine sulfate (1:1) (salt);Vinblastine 5;Rozevin sulfate; |
| EINECS: | 205-606-0 |
| Density: | 1.37 g/cm3 |
| Melting Point: | 267°C (dec.)(lit.) |
| Solubility: | water: 10 mg/mL |
| Appearance: | crystalline solid |
| Hazard Symbols: |
 Xn, T
|
| Risk Codes: | 22-37/38-41-61-36/37/38-63-23/24/25 |
| Safety: | 26-36/39-53-45-37/39-36/37/39 |
| PSA: | 237.08000 |
| LogP: | 4.35970 |
- 144851-82-1METHYL2-AMINO-3-FLUOROBENZOATE
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| With hydrogen; palladium on activated charcoal In ethanol at 20℃; for 0.75h; | 89% |
| Conditions | Yield |
|---|---|
| Stage #1: exo-catharanthine; vindoline With hydrogenchloride; iron(III) chloride; 2,2,2-trifluoroethanol for 2h; Stage #2: With sodium tetrahydroborate; oxygen at 0℃; for 0.5h; | 50% |
- 124096-76-0
(+)-(9R)-3-oxo-9-methoxycarbonylindolizino<8,7-b>indole
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 7 steps 1.1: triethylamine; dmap / dichloromethane / 14 h / 20 °C 2.1: lithium diisopropyl amide / tetrahydrofuran / 12 h 3.1: trifluoroacetic acid / dichloromethane / 16 h 4.1: trimethoxonium tetrafluoroborate; 2,6-di-tert-butyl-pyridine / dichloromethane / 12 h 4.2: 0.5 h 5.1: [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I); 2-bromopyridine-N-oxide; methanesulfonic acid; silver trifluoromethanesulfonate / 5 h / 20 °C 5.2: 3 h / 20 °C 6.1: potassium tert-butylate / tetrahydrofuran / 2 h 7.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 7.2: 0.5 h / 0 °C View Scheme |
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 4 steps 1.1: trimethoxonium tetrafluoroborate; 2,6-di-tert-butyl-pyridine / dichloromethane / 12 h 1.2: 0.5 h 2.1: [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I); 2-bromopyridine-N-oxide; methanesulfonic acid; silver trifluoromethanesulfonate / 5 h / 20 °C 2.2: 3 h / 20 °C 3.1: potassium tert-butylate / tetrahydrofuran / 2 h 4.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 4.2: 0.5 h / 0 °C View Scheme |
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1.1: [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I); 2-bromopyridine-N-oxide; methanesulfonic acid; silver trifluoromethanesulfonate / 5 h / 20 °C 1.2: 3 h / 20 °C 2.1: potassium tert-butylate / tetrahydrofuran / 2 h 3.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 3.2: 0.5 h / 0 °C View Scheme |
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1.1: potassium tert-butylate / tetrahydrofuran / 2 h 2.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 2.2: 0.5 h / 0 °C View Scheme |
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 6 steps 1.1: lithium diisopropyl amide / tetrahydrofuran / 12 h 2.1: trifluoroacetic acid / dichloromethane / 16 h 3.1: trimethoxonium tetrafluoroborate; 2,6-di-tert-butyl-pyridine / dichloromethane / 12 h 3.2: 0.5 h 4.1: [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I); 2-bromopyridine-N-oxide; methanesulfonic acid; silver trifluoromethanesulfonate / 5 h / 20 °C 4.2: 3 h / 20 °C 5.1: potassium tert-butylate / tetrahydrofuran / 2 h 6.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 6.2: 0.5 h / 0 °C View Scheme |
- 143-67-9
vinblastine
| Conditions | Yield |
|---|---|
| Multi-step reaction with 5 steps 1.1: trifluoroacetic acid / dichloromethane / 16 h 2.1: trimethoxonium tetrafluoroborate; 2,6-di-tert-butyl-pyridine / dichloromethane / 12 h 2.2: 0.5 h 3.1: [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I); 2-bromopyridine-N-oxide; methanesulfonic acid; silver trifluoromethanesulfonate / 5 h / 20 °C 3.2: 3 h / 20 °C 4.1: potassium tert-butylate / tetrahydrofuran / 2 h 5.1: hydrogenchloride; 2,2,2-trifluoroethanol; iron(III) chloride / 2 h 5.2: 0.5 h / 0 °C View Scheme |
| Conditions | Yield |
|---|---|
| With diethylzinc In hexane; dichloromethane at 0 - 20℃; Inert atmosphere; | A 18% B n/a C n/a |
- 143-67-9
vinblastine
- 55383-37-4
desacetylvinblastine monohydrazide
| Conditions | Yield |
|---|---|
| With hydrogenchloride; sodium nitrite In methanol; water at 0℃; for 0.2h; pH=7.6; |
- 83150-76-9Octreotide acetate
- 119904-90-41-Azabicyclo[2.2.2]octan-3-amine,hydrochloride (1:2), (3S)-
- 330-54-1Diuron
- 108-32-7Carbonic acid cyclic propylene ester
- 42288-26-6N-(4-Cyanophenyl)glycine
- 52602-39-84-Hydroxycarbazole
- 8000-29-1Citronella oil
- 5521-55-15-Methyl-2-pyrazinecarboxylic acid
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Chemistry
Molecular Structure of Vinblastine sulfate (CAS NO.143-67-9):
.png)
Molecular formula: C46H60N4O13S
Molecular Weight: 909.05
Index of Refraction: 1.671
Molar Refractivity: 220.74 cm3
Molar Volume: 590 cm3
Surface Tension: 70.9 dyne/cm
Density: 1.37 g/cm3
NECS: 205-606-0
Melting point: 267 °C (dec.)(lit.)
Alpha: -21.7 o (c=2, CH3OH 21 oC)
Storage temp: 2-8°C
Solubility: H2O: 10 mg/mL
Water Solubility: >=1 g/100 mL at 24.5 oC
Appearance: white powder
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LDLo | intravenous | 500ug/kg (0.5mg/kg) | BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Vsesoyuznyi Institut Nauchnoi i Tekhnicheskoi Informatsii Vol. #3713-83, |
| hamster | LD50 | intraperitoneal | 4300ug/kg (4.3mg/kg) | Cancer Letters Vol. 2, Pg. 267, 1977. | |
| human | TDLo | intravenous | 557ug/kg (0.557mg/kg) | BLOOD: LEUKOPENIA SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Cancer Chemotherapy Reports. Vol. 29, Pg. 111, 1963. |
| mouse | LD50 | intraperitoneal | 2700ug/kg (2.7mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979. | |
| mouse | LD50 | intravenous | 9500ug/kg (9.5mg/kg) | Cancer Research. Vol. 39, Pg. 3575, 1979. | |
| mouse | LD50 | oral | 423mg/kg (423mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 68, 1969. | |
| mouse | LD50 | subcutaneous | 324mg/kg (324mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 68, 1969. | |
| rat | LD50 | intraperitoneal | 1mg/kg (1mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Vsesoyuznyi Institut Nauchnoi i Tekhnicheskoi Informatsii Vol. #3713-83, |
| rat | LD50 | intravenous | 37mg/kg (37mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 68, 1969. | |
| rat | LD50 | oral | 305mg/kg (305mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 68, 1969. | |
| rat | LD50 | subcutaneous | 355mg/kg (355mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 68, 1969. |
Consensus Reports
IARC Cancer Review: Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 7 ,1987,p. 371.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 26 ,1981,p. 349.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of chemicals to Man . 26 ,1981,p. 349.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.
Safety Profile
Poison by ingestion, intraperitoneal, and intravenous routes. An experimental teratogen. Human systemic effects by intravenous route: blood leukopenia and hair changes. Experimental reproductive effects. Questionable carcinogen. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also vincaleukoblastine and sulfates.
Hazard Codes: 
Xn,
T
Risk Statements: 22-37/38-41-61-36/37/38-63-23/24/25
R22:Harmful if swallowed.
R37/38:Irritating to respiratory system and skin.
R41:Risk of serious damage to the eyes.
R61:May cause harm to the unborn child.
R36/37/38:Irritating to eyes, respiratory system and skin.
R63:Possible risk of harm to the unborn child.
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-36/39-53-45-37/39-36/37/39
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S53:Avoid exposure - obtain special instructions before use.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S37/39:Wear suitable gloves and eye/face protection.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
RIDADR: 1544
WGK Germany: 3
RTECS: YY8400000
F: 8-10
HazardClass: 6.1(a)
PackingGroup: II
Specification
Vinblastine sulfate , with CAS number of 143-67-9, can be called Vincaleukoblastine derivative ; vincaleukoblastine, (2'beta)- ; Vincaleukoblastine derivative ; Vincaleukoblastine sulfate (1:1) (salt) ; Vinblastine 5 ; Rozevin sulfate . It is an antineoplastic agents for the treatment of Hodgkin's disease, choriocarcinoma and lymphosarcoma, it also has some effect on acute leukemia, breast cancer.